Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered computational target discovery, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management will engage in a fireside chat that will be accessible on-demand through Compugen's website starting September 5, 2025, at 7:00 AM ET. The presentation will remain available for 90 days on the company's Investor Relations section.

HOLON, Israel, Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference.

The fireside chat will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Friday, September 5, 2025, 7:00 AM ET for 90 days.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen^™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302540915.html

SOURCE Compugen Ltd.

FAQ

When is Compugen's (CGEN) presentation at the H.C. Wainwright Conference?

Compugen's fireside chat will be available on-demand starting September 5, 2025, at 7:00 AM ET.

How long will Compugen's (CGEN) H.C. Wainwright Conference presentation be available?

The presentation will be available for 90 days on Compugen's website.

Where can I watch Compugen's (CGEN) H.C. Wainwright Conference presentation?

The fireside chat will be accessible through the Investor Relations section of Compugen's website at www.cgen.com.

What type of company is Compugen (CGEN)?

Compugen is a clinical-stage cancer immunotherapy company that pioneers predictive computational target discovery using AI/ML technology.